Active ingredientOpicaponeCat. No. P-O024-001CAS 923287-50-7Family · Pharmaceutical analytical standards
Opicapone
A catechol-O-methyltransferase (COMT) inhibitor, used as an add-on to levodopa in Parkinson's disease; approved in Europe in 2016 and in the United States in 2020. This family brings together the active ingredient, metabolites and other impurities.
Did you know?It was born in Portugal after 11 years of research and was the second medicine developed in the country to win European approval, after the antiepileptic eslicarbazepine.
Go to the active ingredient →Active ingredientOpicaponeCat. No. P-O024-001CAS 923287-50-7
Active ingredientOpicapone SulfateCat. No. P-O024-002
MetaboliteOpicapone 3-O-GlucuronideCat. No. P-O024-003CAS 1428009-74-8
Impurity2,5-Dichloro-4,6-dimethylnicotinamideCat. No. P-O024-006CAS 175204-44-1
ImpurityOpicapone Impurity 1Cat. No. P-O024-007CAS 923288-59-9
Impurity3-Acetyl-4-hydroxy-5-methoxybenzoic acidCat. No. P-O024-008CAS 874518-62-4
Impurity4-Amino-2-phenylfuran-3-carboxamideCat. No. P-O024-009CAS 1962082-05-8
ImpurityOpicapone Impurity 2Cat. No. P-O024-010CAS 91591-66-1
ImpurityOpicapone Impurity 3Cat. No. P-O024-011CAS 893767-99-2
ImpurityOpicapone Impurity 4Cat. No. P-O024-012CAS 1391712-50-7
ImpurityOpicapone Impurity 5Cat. No. P-O024-013CAS 952091-17-7
ImpurityOpicapone Impurity 6Cat. No. P-O024-014CAS 1402714-41-3
ImpurityOpicapone Impurity 7Cat. No. P-O024-015CAS 2356241-51-3
ImpurityOpicapone Impurity 8Cat. No. P-O024-016CAS 2824922-39-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.